CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 68 enrolled
Drug / intervention
gallium Ga 68-edotreotide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01869725
NCT01869725Phase 2Completed
CompareCT.gov

Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors

Sue O'Dorisio·interventional·Posted Jun 5, 2013·Updated Sep 22, 2021

In Brief

A Phase 2 clinical trial evaluating gallium Ga 68-edotreotide, positron emission tomography/computed tomography, and 3 other interventions for Adult Medulloblastoma and 4 related conditions. Completed, enrolled 68 participants across 1 site.

Detailed Summary

This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 5, 2013
Enrollment StartApr 1, 2013
Primary CompletionDec 26, 2018
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 13.1 years ago

Interventions

gallium Ga 68-edotreotidedrug

Given IV

positron emission tomography/computed tomographyprocedure

Undergo gallium Ga 68-edotreotide PET/CT scan

indium In 111 pentetreotideradiation

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

computed tomographyprocedure

Undergo indium In 111 pentetreotide contrast-enhanced CT scan

contrast-enhanced magnetic resonance imagingprocedure

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan